SXTP PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

SXTP ▼ -9.93% at T+20d

NEUTRAL call ✗ call lost -9.93% · α vs SPY -19.35% · entry $1.75 → $1.58

Next anchor: T+60d in 13d

Currently $1.36 · -22.29% from $1.75 entry

Entry anchored
Mar 30, 03:59 PM ET
via Databento tick

T+1d

+6.86%

call +6.86% · α +6.11%

$1.87

settled 2mo ago

T+5d

+3.43%

call +3.43% · α -0.52%

$1.81

settled 2mo ago

T+20d

-9.93%

call -9.93% · α -19.35%

$1.58

settled 6w ago

T+60d

—

call — · α —

—

in 13d

Price Chart

Loading chart...

Executive Summary

Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, driven by higher sales and pricing, while gross profit remained flat at $223.8K. Net loss narrowed to $7.37M from $7.96M in 2024, primarily due to lower non-cash R&D charges, despite higher selling expenses. The company exhausted its $4M ATM shelf capacity and highlighted clinical progress in babesiosis, but continues to face going-concern uncertainty.

Key Financial Metrics

Revenue

$1.0M

+65.0% YoY

EPS

$-11.73

Actionable Insight

While revenue growth and reduced losses are positive, the company remains deeply unprofitable and reliant on dilutive financing. Traders should monitor the upcoming Phase 2 interim data (possible catalyst in Q3) and watch for new capital raises. The narrow loss improvement was largely due to non-recurring 2024 charges — underlying fundamentals remain weak.

Key Facts

FY2025 net product revenue increased 65% YoY to $1,005,000 from $607,600 in 2024
Gross profit was $223.8K in 2025 vs. $222.8K in 2024, despite non-recurring inventory write-offs
Operating expenses decreased to $8.4M from $10.0M in 2024, driven by $2.9M lower R&D costs (non-recurring charges in 2024)
Net loss narrowed to $7.37M ($11.73/share) from $7.96M ($74.17/share) in 2024
Company raised $4.03M via ATM, exhausting current shelf capacity
2.64M shares outstanding as of March 30, 2026
All patients in expanded access study for relapsing babesiosis were cured with tafenoquine
Interim data from Phase 2 B-FREE study expected as early as September 2026
Partnerships with GoodRx and Runway Health expanded ARAKODA® distribution
FDA approval risk, going-concern doubt, and lack of manufacturing capacity remain key risks

Financial Impact

Revenue up 65% to $1.005M; net loss improved by $590K; $4.03M in dilutive ATM financing

revenuegross_profitoperating_expensesnet_lossdilutionshares_outstanding

Risk Factors

Substantial doubt about going-concern basis per forward-looking statements
Heavy reliance on dilutive ATM financing; shelf capacity exhausted, next raise likely dilutive
No manufacturing capacity, creating supply chain and timing risks
Clinical trial outcomes uncertain; regulatory approval not guaranteed
Revenue base still very small ($1M) despite 65% growth

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3265329

4 reports for SXTP

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SXTP — sortable, filterable
	Type				Now
May 26, 2026 18d ago	Press Release NEUTRAL ★ 4/10	$1.50 $1.46	▼ −2.67%	▼ −3.75%	$1.36 (−9.33%)
May 15, 2026 28d ago	Press Release BEARISH ★ 6/10	$1.39 $1.48	▼ −6.47%	▼ −5.51%	$1.36 (+2.16%)
Mar 31, 2026 10w ago	Press Release MIXED ★ 5/10	$1.75 $1.81	▲ +3.43%	▼ −0.52%	$1.36 (−22.29%)
Mar 18, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$2.12 $1.55	▼ −26.89%	▼ −26.17%	$1.36 (−35.85%)

US Market Status

Market Closed — Opens Mon (48h 53m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access